Skip to main content
. 2021 Jun 2;8:658747. doi: 10.3389/fmed.2021.658747

Table 2.

Base-case results.

Outcomes ABE + FUL RIB + FUL PAL + FUL FUL
LYs 4.09 4.29 3.65 3.20
QALYs 2.36 2.33 1.92 1.68
Cost, $ $541,890 $541,372 $441,194 $281,306
Incremental cost / $518 $100,696 $260,584
Incremental QALYs / 0.03 0.44 0.68
Incremental cost per LY, $ / Dominated $229,689 $291,323
Incremental cost per QALY, $ / $19,314 $229,039 $381,450

LYs, life years; QALYs, quality-adjusted life years; ABE, abemaciclib; RIB, ribociclib; PAL, palbociclib; FUL, fulvestrant.